Nicotine Lozenge to Reduce Smokeless Tobacco Use

Completed · Phase 2

Conditions studied: Tobacco Use Disorder

In brief

Smokeless tobacco (ST), which includes both chewing tobacco and snuff, has as many health risks associated with its use as cigarettes. While there are many treatment programs that focus on stopping tobacco use, there are no interventions that specifically focus on reducing tobacco use. This study will evaluate the effectiveness of nicotine lozenge at reducing tobacco use in ST users.

Key facts

Study ID

NCT00218283

Run by

National Institute on Drug Abuse (NIDA)

People needed

100

Starts

2005-01-01

Expected to finish

2007-06-01

Last updated by the study team

2017-01-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• No interest in stopping ST use within 90 days of study entry
• Using ST at least 6 times a day in the 6 months prior to study entry
• Willing to use contraception throughout the study

You may not qualify if…

• Current use of tobacco or nicotine products, other than ST
• Current unstable medical condition
• Use of any medication that may affect tobacco use or be affected by a reduction in tobacco use
• Meets DSM-IV diagnostic criteria for any psychiatric disorder or substance abuse disorder within 6 months of study entry
• Use of any psychotropic medication within 6 months of study entry
• Pregnant or breastfeeding

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.